Wednesday, 2 May 2012

Levothyroxine Tablets 50mcg, 100mcg (Actavis UK Ltd)





Levothyroxine 50micrograms and 100micrograms tablets




Read all of this leaflet carefully before you start taking this medicine.



  • Keep this leaflet. You may need to read it again.

  • If you have any further questions, ask your doctor or pharmacist.

  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.




Index



  • 1 What Levothyroxine tablets are and what they are used for

  • 2 Before you take

  • 3 How to take

  • 4 Possible side effects

  • 5 How to store

  • 6 Further information





What Levothyroxine tablets are and what they are used for



Levothyroxine belongs to a group of medicines called thyroid hormones, which are used to treat hypothyroidism (underactive thyroid gland).





Before you take




Do not take Levothyroxine tablets and tell your doctor if you:



  • are allergic (hypersensitive) to anhydrous levothyroxine sodium or any other ingredients in Levothyroxine tablets (see section 6).


  • are suffering from a condition that produces excessive quantities of thyroid hormone (thyrotoxicosis).


  • are suffering from untreated adrenal problems.




Check with your doctor or pharmacist before taking Levothyroxine tablets if you:



  • have any heart problems or have had a heart attack


  • suffer from high blood pressure


  • are elderly or have severe long term hypothyroidism (underactive thyroid gland)


  • are suffering from a condition caused by an underactive adrenal gland such as panhypopituitarism


  • have diabetes.




Taking other medicines



Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Especially:



  • medicines to treat diabetes (eg insulin, metformin)

  • medicines to control your heart rate such as digoxin

  • tricyclic antidepressants (eg amitriptyline, dosulepin)

  • medicines that stimulate the sympathetic nervous system such as adrenaline (epinephrine)

  • anticoagulants (used to thin the blood) such as warfarin, dicoumarol, acenocoumarol, phenindione

  • sodium polystyrene sulphonate (used to treat kidney disease)

  • colesytramine (used to treat diarrhoea)

  • medicines to treat stomach ulcers such as sucralfate, cimetidine

  • aluminium hydroxide (used to treat heartburn)

  • medicines containing calcium carbonate

  • “iron” tablets (containing ferrous sulphate)

  • medicines to treat epilepsy such as carbamazepine, phenytoin, phenobarbital, primidone

  • rifampicin (used to treat serious infections)

  • aspirin and phenylbutazone (medicines to reduce inflammation)

  • propranolol (a beta-blocker)

  • medicines containing oestrogen (eg HRT, oral contraceptives – “the pill”)

  • amiodarone (used to treat some heart conditions)

  • ketamine (an anaesthetic)

  • lovastatin (used to reduce cholesterol)

  • corticosteroids (eg hydrocortisone, prednisolone)

  • medicines containing testosterone and mesterolone.




Pregnancy and breast-feeding



If you are pregnant particularly in the first three months, planning to become pregnant or are breast-feeding tell your doctor or pharmacist before taking this medicine.





Sugar intolerance



If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine, as it contains lactose.






How to take



Always take Levothyroxine tablets exactly as your doctor has told you. If you are not sure, check with your doctor or pharmacist.



Swallow the tablets with water, before food.




Doses:



Adults:

Initially 50-100micrograms a day increased by 50micrograms every 3-4 weeks up to a maximum of 150-300micrograms a day, until normal metabolism is maintained.



Patients over 50 years:

Initally no more than 50micrograms a day should be taken.



Patients over 50 years with heart disease:

25micrograms a day or 50micrograms every other day should be taken, this may be increased by 25micrograms a day every 4 weeks.



Congenital hypothyroidism in infants:

Initially 25micrograms a day, increased by 25micrograms every 2-4 weeks until mild toxic symptoms appear, the dose will then be reduced slightly.



Juvenile myxoedema:

Initially 25micrograms a day, increased by 25micrograms every 2-4 weeks until mild toxic symptoms appear, the dose will then be reduced slightly.



In children over 1 year, initially 2.5-5micrograms per kg of bodyweight a day should be taken.





If you take more than you should



If you (or someone else) swallow a lot of the tablets at the same time, or you think a child may have swallowed any, contact your nearest hospital casualty department or tell your doctor immediately. Symptoms of an overdose include:



  • Mild to moderate overdose: fever, angina, a racing heart, irregular heart beats, muscle cramps, headache, restlessness, flushing, sweating, diarrhoea.


  • Severe overdose: thyroid crisis including irregular heart beats, heart failure, collapse, coma, death.

Signs and symptoms of increased thyroid hormone levels may not be seen for up to 5 days.





If you forget to take the tablets



Do not take a double dose to make up for a forgotten dose. If you forget to take a dose take it as soon as you remember it and then take the next dose at the right time.





If you stop taking the tablets



Talk to your doctor before you stop taking the tablets and follow their advice.






Possible side effects



Like all medicines, Levothyroxine tablets can cause side-effects, although not everybody gets them. Please tell your doctor or pharmacist if you notice any of the following effects or any effects not listed.



Tell your doctor if you notice any of the following side effects:



  • Allergic reactions: including a rash which may be itchy or swelling.

The following side effects may be due to high doses and usually disappear after reducing the dose or stopping the tablets. Tell your doctor if you notice:



  • Heart: a racing heart, irregular heart beats, palpitations, anginal pain.

  • Central nervous system: headache, restlessness, excitability, difficulty in sleeping, flushing, sweating, fever, involuntary shakiness, heat intolerance.

  • Stomach and intestines: diarrhoea, being sick, excessive weight loss.

  • Muscle and bone: muscle cramps, muscular weakness.

  • Other: partial hair loss during first few months of therapy.




How to store



  • Keep out of the reach and sight of children.

  • Do not store above 25ºC. Store in the original package. Keep container in the outer carton.

  • Do not use Levothyroxine tablets after the expiry date stated on the label/carton/bottle. The expiry date refers to the last day of that month.

  • Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.




Further information




What Levothyroxine tablets contain



  • The active substance (the ingredient that makes the tablets work) is anhydrous levothyroxine sodium. Each tablet contains either 50micrograms or 100micrograms of the active substance.


  • The other ingredients are lactose, magnesium stearate, maize starch, stearic acid and pregelatinised maize starch.




What Levothyroxine tablets look like and contents of the pack



50microgram tablets are white, circular, biconvex, uncoated tablets.



100microgram tablets are white, circular, shallow convex, uncoated tablets.



Pack size is 28 and 1000 tablets.





Marketing Authorisation Holder and Manufacturer




Actavis

Barnstaple

EX32 8NS

UK





This leaflet was last revised in August 2007.



In addition to advice from your doctor or pharmacist, you can also contact the association listed below for more information on thyroid disease:




The British Thyroid Foundation

PO Box 97

Clifford

Wetherby

West Yorkshire

LS23 6XD

Tel/Fax:01423 709707





If you would like a leaflet with larger text, please contact 01271 311257.






Actavis

Barnstaple

EX32 8NS

UK



50129603






Tuesday, 1 May 2012

Beechams Ultra All in One Hot Cranberry and Blackcurrant Powder for Oral Solution





1. Name Of The Medicinal Product



Beechams Ultra All in One Hot Cranberry and Blackcurrant, powder for oral solution.


2. Qualitative And Quantitative Composition



Each single-dose sachet contains paracetamol 1000 mg, guaifenesin 200 mg and phenylephrine hydrochloride 12.2 mg.



Excipients:



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Powder for oral solution.



Grey to purple fine powder with a cranberry odour.



4. Clinical Particulars



4.1 Therapeutic Indications



Beechams Ultra All in One Hot Cranberry and Blackcurrant is indicated in adults and children aged 16 years and older for the short-term relief of the symptoms of influenza, feverishness, chills and colds including headache, chesty cough, sore throat pain, aches and pains, nasal congestion, sinusitis and its associated pain, and acute nasal catarrh.



4.2 Posology And Method Of Administration



Posology



Adults (including the elderly) and children aged 16 years and over:



One sachet, dissolved in a standard mug of hot water but not boiling water (approximately 250 ml), to be taken every four to six hours, up to a maximum of four sachets in any 24 hours.



Minimum dosing interval: four hours



Do not exceed the stated dose.



Maximum duration of continued use without medical advice: 7 days.



Paediatric population



Children under 16 years of age:



Not to be given to children under 16 years of age, except under medical advice.



The safety of Beechams Ultra All in One Hot Cranberry and Blackcurrant in children aged from birth to 16 years of age has not been established (see section 5.1). No data are available.



Populations



Patients with hepatic impairment:



Patients who have been diagnosed with hepatic impairment must seek medical advice before taking this medicine. The restrictions related to the use of such combinations in patients with hepatic impairment are primarily a consequence of the paracetamol content of the product (see Section 4.4 Special Warnings and Precautions for Use).



Patients with renal impairment:



Patients who have been diagnosed with renal impairment must seek medical advice before taking this medicine. The restrictions related to the use of such combinations in patients with renal impairment are primarily a consequence of the paracetamol content of the product (see Section 4.4 Special Warnings and Precautions for Use).



Method of administration



For oral use. Dissolve one sachet in a standard mug of hot water but not boiling water (approximately 250 ml). A purple solution slightly cloudy with an odour of cranberry will be obtained.



To be taken as a warm drink.



4.3 Contraindications



- Hypersensitivity to any of the drug substances or to any of the excipients.



- Use in patients who are taking, or have taken, within the last two weeks, monoamine oxidase inhibitors (MAOIs) (see Section 4.5 Interaction with other Medicaments and other forms of interaction).



- Concomitant use of other sympathomimetic decongestants.



- Phaeochromocytoma.



- Closed angle glaucoma.



- Hepatic or severe renal impairment, hypertension, hyperthyroidism, diabetes, heart disease or those taking tricyclic antidepressants or beta-blocking drugs.



Contains sucrose: Patients with rare hereditary problems of fructose intolerance, glucose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.



Contains a source of phenylalanine. May be harmful to people with phenylketonuria.



4.4 Special Warnings And Precautions For Use



Medical advice should be sought before taking this product in patients with the following conditions: hypertension, cardiovascular disease, diabetes, hyperthyroidism, angle closure glaucoma, phaeochromocytoma, an enlargement of the prostate gland, occlusive vascular disease (e.g. Raynaud's Phenomenon).



Patients suffering from chronic cough or asthma should consult a physician before taking this product. Do not take with a cough suppressant.



Care is advised in the administration of paracetamol to patients with renal or hepatic impairment. Underlying liver disease increases the risk of paracetamol related liver damage.



Use with caution in patients taking beta-blockers and other antihypertensive drugs or tricyclic antidepressants (see Section 4.5 Interaction with other Medicaments and other forms of interaction).



This product should not be used by patients taking other sympathomimetics (e.g. decongestants, appetite suppressants and amphetamine-like psychostimulants) (see Section 4.5 Interaction with other Medicaments and other forms of interaction).



Contains paracetamol.



If symptoms persist or are accompanied by a fever, rash or persistent headache. consult your doctor. Prolonged use of this product, except under medical supervision, may be harmful. Maximum duration of use without medical advice is 7 days.



Do not take other medicines containing paracetamol, decongestants or cough and cold products while using this product.



Patients should stop using the product and consult a health care professional if cough lasts for more than 5 days or comes back, or is accompanied by a fever, rash or persistent headache.



Do not take with a cough suppressant.



This product should only be used when clearly necessary.



Do not exceed the stated dose.



This medicinal product contains 117 mg sodium per dose. To be taken into consideration by patients on a controlled sodium diet.



Paediatric Population



For children aged 16 years and over:



See above.



Keep all medicines out of the sight and reach of children.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



No interaction studies have been performed.



Paediatric Population



No interaction studies have been performed.



Paracetamol:



The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged, regular, daily use of paracetamol with increased risk of bleeding; occasional doses have no significant effect.



The hepato-toxicity of paracetamol may be potentiated by excessive intake of alcohol. The speed of absorption of paracetamol may be increased by metoclopramide or domperidone and absorption reduced by colestyramine. Pharmacological interactions involving paracetamol with a number of other drugs have been reported. These are considered to be of unlikely clinical significance in acute use at the dosage regimen proposed.



Phenylephrine Hydrochloride:



Phenylephrine hydrochloride should be used with caution in combination with the following drugs as interactions have been reported
















Monoamine oxidase inhibitors




Hypertensive interactions occur between sympathomimetic amines such as phenylephrine hydrochloride and monoamine oxidase inhibitors (see Section 4.3 Contraindications).




Sympathomimetic amines




Concomitant use of phenylephrine hydrochloride with other sympathomimetic amines can increase the risk of cardiovascular side effects (see Section 4.4 Special Warnings and Precautions for Use).




Beta-blockers, and other antihypertensives (including debrisoquine, guanethidine, reserpine, methyldopa




Phenylephrine hydrochloride may reduce the efficacy of beta-blocking drugs and antihypertensive drugs. The risk of hypertension and other cardiovascular side effects may be increased (see Section 4.4 Special Warnings and Precautions for Use).




Tricyclic antidepressants (e.g. amitriptyline




May increase the risk of cardiovascular side effects with phenylephrine hydrochloride (see Section 4.4 Special Warnings and Precautions for Use).




Ergot alkaloids (ergotamine and methylsergide)




Increased risk of ergotism




Digoxin and cardiac glycoside




Increase the risk of irregular heartbeat or heart attack



If urine is collected within 24 hours of a dose of this product, a metabolite may cause a colour interference with laboratory determinations of 5 hydroxyindoleacetic acid (5-HIAA) and vanillymandelic acid (VMA).



Guaifenesin



No significant interactions with other drugs have been noted for Guaifenesin.



4.6 Pregnancy And Lactation



Pregnancy:



There are limited data from the use of paracetamol, phenylephrine hydrochloride and guaifenesin in pregnant women.



Beechams Ultra All in One Hot Cranberry is not recommended during pregnancy without medical advice.



Epidemiological studies in human pregnancy have shown no ill effects due to paracetamol used in the recommended dosage, but patients should follow the advice of their doctor regarding its use. The safety of phenylephrine during pregnancy has not been established.



Breastfeeding:



Physiochemical data suggest excretion of paracetamol, phenylephrine hydrochloride or guaifenesin and their metabolites in human milk.



A risk to the newborn/infants cannot be excluded.



Paracetamol and Phenylephrine hydrochloride may be excreted in breast milk.



Beechams Ultra All in One Hot Cranberry should not be used during breast-feeding without medical advice.



4.7 Effects On Ability To Drive And Use Machines



Beechams Ultra All in One Hot Cranberry and Blackcurrant may have a moderate influence on the ability to drive and use machines. Patients should be advised not to drive or use machines if affected by dizziness.



4.8 Undesirable Effects



The drug substances paracetamol, phenylephrine hydrochloride and guaifenesin are usually well tolerated in normal use.



Adverse events from historical clinical trial data are both infrequent and from small patient exposure. Events reported from extensive post-marketing experience at therapeutic/labelled dose and considered attributable are tabulated below by MedDRA System Organ Class. Due to limited clinical trial data, the frequency of these adverse events is not known (cannot be estimated from available data), but post-marketing experience indicates that adverse reactions to paracetamol are rare and serious reactions are very rare.



Paracetamol



The frequency of these paracetamol-related adverse reactions is unknown but based on estimate from post-marketing data are likely to be very rare.
















Body System




Undesirable effect




Blood and lymphatic system disorders




Thrombocytopenia.



Agranulocytosis.



These are not necessarily causally related to paracetamol




Immune system disorders




Anaphylaxis.



Cutaneous hypersensitivity reactions including skin rashes, angioedema and Stevens Johnson Syndrome.




Respiratory, thoracic and mediastinal disorders




Bronchospasm in patients sensitive to aspirin and other NSAIDs.




Hepatobiliary disorders




Hepatic dysfunction




Gastrointestinal disorders




Acute pancreatitis



Guaifenesin



The frequency of these guaifenesin-related adverse reactions is unknown but based on estimate from post-marketing data are likely to be rare.














Body System




Undesirable effect




Immune system disorders




Allergic reactions, angioedema, anaphylactic reactions.




Respiratory, thoracic and mediastinal disorders




Dyspnoea*




Gastrointestinal disorders




Nausea, vomiting, abdominal discomfort




Skin and subcutaneous disorders




Rash, urticaria



*dyspnoea has been reported in association with other symptoms of hypersensitivity



Phenylephrine hydrochloride:



The following adverse events have been observed in clinical studies involving phenylephrine hydrochloride and are considered to be the most commonly occurring. Adverse events are listed below by MedDRA System Organ Class.














Body System




Undesirable effect




Psychiatric disorders




Nervousness, irritability, restlessness, and excitability




Nervous system disorders




Headache, dizziness, insomnia




Cardiac disorders




Increased blood pressure




Gastrointestinal disorders




Nausea, vomiting, diarrhoea



Adverse reactions identified during post-marketing use are listed below. The frequency of these reactions is unknown but likely to be rare.














Body System




Undesirable effect




Eye disorders




Mydriasis, acute angle closure glaucoma, most likely to occur in those with closed angle glaucoma (see Section 4.3 Contraindications and Section 4.4 Special Warnings and Precautions for Use).




Cardiac disorders




Tachycardia, palpitations.




Skin and subcutaneous disorders




Allergic reactions (e.g., rash, urticaria, allergic dermatitis).



Hypersensitivity reactions including cross-sensitivity with other sympathomimetics may occur.




Renal and urinary disorders




Dysuria, urinary retention. This is most likely to occur in those with bladder outlet obstruction such as prostatic hypertrophy.



Paediatric population



See above.



4.9 Overdose



Paracetamol



Immediate medical attention (in-hospital, if possible) is required in the event of overdose, even if there are no significant early symptoms. There may be no early symptoms following a life-threatening overdose.



Ingestion of more than 12 g paracetamol (24 standard 500 mg tablets, or 12 sachets) or more than 150 mg paracetamol per kg body weight (9 g of paracetamol in a 60 kg individual), whichever is the smaller, can cause severe liver damage. Liver damage (as demonstrated by a rise in plasma transaminase levels) may be apparent between 8 and 36 hours following overdose. Biochemical evidence of maximal damage, however, may not be attained until 72-96 hours after ingestion of the overdose.



Intravenous N-acetylcysteine (NAC) is effective when initiated within 8 hours of the overdose. Efficacy declines progressively after this time, but NAC may provide some benefit up to and possibly beyond 24 hours. Oral methionine is also effective provided that it is given within 10 to 12 hours of the overdose. Activated charcoal should be considered if the dose of paracetamol ingested exceeds 12 g or 150 mg/kg, whichever is the smaller, and the procedure can be undertaken within one hour of the overdose. There is little evidence that undertaking gastric lavage will be of benefit to a patient in whom paracetamol is known to have been the only substance ingested.



Symptoms of paracetamol overdose in the first 24 hours may include pallor, nausea, vomiting, anorexia and abdominal pain. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, coma and death. Liver damage results when excess quantities pf a toxic metabolite (usually adequately detoxified by glutathione when normal doses of paracetamol are ingested) become irreversibly bound to liver tissue. Acute renal failure with acute tubular necrosis may develop even in the absence of severe liver damage. Cardiac arrythmias and pancreatitis have been reported.



Phenylephrine hydrochloride



Phenylephrine hydrochloride overdosage is likely to result in effects similar to those listed under adverse reactions. Additional symptoms of phenylephrine hydrochloride overdose include headache, an increase in blood pressure and possibly associated reflex bradycardia. In severe cases confusion, hallucinations, seizures and arrhythmias may occur.



Treatment should be as clinically appropriate. Raised blood pressure should be treated with an alpha receptor antagonist such as intravenous phentolamine. Reduction of blood pressure should, by reflex mechanism, increase the heart rate but if necessary this can be facilitated by the administration of atropine.



Guaifenesin



Very large doses of guaifenesin cause nausea and vomiting. Vomiting would be treated by fluid replacement and monitoring of electrolytes if indicated.



Paediatric population



See above.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: Other analgesics and antipyretics, paracetamol, combinations excluding psycholeptics.



ATC Code: N02BE51.



Paracetamol



Paracetamol is an analgesic, antipyretic drug substance.



The antipyretic activity of paracetamol is thought to be mediated by its ability to selectively inhibit prostaglandin synthesis in the central nervous system.



The precise mechanism for the analgesic properties of paracetamol remains to be established. Data suggest that central prostaglandin synthetase inhibition is likely to be of primary importance. Paracetamol is a weak inhibitor of COX-1 and COX-2 leading to the suggestion that there may be another form of COX which is more sensitive to inhibition by paracetamol.



Paracetamol does not appear to inhibit the peripheral generation of prostaglandins, e.g., it does not alter the gastric mucosal generation of prostaglandins and serious gastro-intestinal adverse events associated with paracetamol are rare. Paracetamol is, therefore, particularly suitable for patients with a history of acid peptic disease or on concomitant medication where peripheral prostaglandin inhibition would be undesirable, e.g. with gastro-intestinal bleeding, cardiovascular disease or in the elderly.



Guaifenesin



Guaifenesin has an expectorant action. It is thought to reduce sputum viscosity by increasing the volume and water content of the bronchial secretion, thereby facilitating the expectoration of sputum.



Phenylephrine hydrochloride



Phenylephrine hydrochloride is a sympathomimetic post-synaptic α-receptor agonist with low cardioselective β-receptor affinity and minimal central stimulant activity. It is a recognised decongestant and acts by vasoconstriction to reduce oedema and nasal swelling.



5.2 Pharmacokinetic Properties



Paracetamol



Absorption and Distribution



Oral paracetamol is readily absorbed from the upper small intestine to give peak plasma concentrations of 15-20 mcg/ml in 30 to 120 minutes after oral administration of a 1000 mg dose in adults. The speed of gastric emptying modifies the rate of absorption. Plasma protein binding is minimal and there is distribution to all tissues.



Metabolism and Excretion



There is limited first-pass metabolism of paracetamol after oral administration and about 80% of a 1000 mg dose is bioavailable. Paracetamol is metabolised primarily in the liver. After a 1000 mg oral dose in adults, 50-60% is recovered in the urine as the glucuronide conjugate, 25-35% as the sulphate conjugate, up to 5% as unchanged paracetamol and 2-5% as the cysteine or mercapturate metabolites.



The latter are formed from the combination of glutathione with the oxidation metabolite of paracetamol, N-acetyl-p-benzoquinoneimine (NAPQI). Excretion via the urine is rapid and the plasma half-life after oral administration is 1-4 hours.



Guaifenesin



Guaifenesin is well-absorbed after oral administration. Guaifenesin had a plasma half-life of approx 1 hour and was not detectable in the blood after 8 hours. No information is available on the distribution of guaifenesin in humans. It appears to undergo both oxidation and demethylation. It is excreted in urine.



Phenylephrine hydrochloride



Phenylephrine hydrochloride is irregularly absorbed from the gastro-intestinal tract after oral administration. It is subject to extensive presystemic metabolism in the gut wall and therefore has a systemic bioavailability of approximately 40% relative to intravenous dosing. Following oral administration, peak plasma concentrations are achieved in 1 - 2 hours. The mean plasma half-life is in the range 2 - 3 hours.



The volume of distribution is large (200 to 500 litres). Penetration of the brain and excretion in breast milk appear to be minimal. Phenylephrine hydrochloride does not cross the placenta. The extent of protein binding is unknown.



Phenylephrine hydrochloride is extensively metabolised in the gut wall and liver. The principal routes of metabolism are sulphation and glucuronidation of the 3-hydroxyl group and oxidative deamination by monoamine oxidase to 3-hydroxymandelic acid and 3-hydroxyphenylglycol. Sulphate conjugates are formed from the metabolites. Excretion is via the kidneys.



Paediatric population



The pharmacokinetic profile of oral paracetamol in children is similar to that seen in adults, whereas in neonates clearance of paracetamol is significantly reduced with a longer half-life seen. Infants have usually developed similar clearances of paracetamol to older children by the age of one year.



5.3 Preclinical Safety Data



Nonclinical data [published in the literature] reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.



Nonclinical safety data on the drug substances in the literature have not revealed any pertinent and conclusive findings which are of relevance to the recommended dosage and use of the product, which have not already been mentioned elsewhere in the SPC.



The toxicity of paracetamol is well documented.



Effects of chronic toxicity in rats and mice include gastrointestinal lesions, blood count changes, degeneration and necrotic changes in testicular and lymphoid tissue in addition to hepatic and renal necrosis.



Long-term studies in rats and mice give no conclusive evidence of carcinogenic effects. There is no evidence of embryo- or foeto-toxicity from paracetamol in animal studies.



Paracetamol hepatotoxicity is directly dependent on the plasma concentration in relation to time. In man, plasma concentrations above 1.2 mmol/l at 4 hours, 0.6 mmol/l at 8 hours and 0.3 mmol/l at 12 hours are criteria for immediate antidote treatment to prevent irreversible damage.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Silica, Colloidal Anhydrous



Maize Starch



Sucrose



Sodium Citrate



Citric Acid



Aspartame (E951)



Saccharin Sodium (E954)



Cranberry Blackcurrant Flavour



Natural Grapeskin Red Colour



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



3 years.



6.4 Special Precautions For Storage



Do not store above 25°C.



6.5 Nature And Contents Of Container



Individual single dose paper/PE/aluminium foil laminate sachets containing 6.6 g of Beechams Ultra All in One Hot Cranberry and Blackcurrant.



Supplied in packs of five or ten sachets.



6.6 Special Precautions For Disposal And Other Handling



No special requirements.



7. Marketing Authorisation Holder



Beecham Group Plc



980 Great West Road



Brentford



Middlesex



TW8 9GS



United Kingdom.



Trading as



GlaxoSmithKline Consumer Healthcare



Brentford



TW8 9GS, UK



8. Marketing Authorisation Number(S)



PL 00079/0670



9. Date Of First Authorisation/Renewal Of The Authorisation

17 /08/2011


10. Date Of Revision Of The Text



17/08/2011




Monday, 30 April 2012

Nitroglycerin Injection USP 0.05% w / v, 10ml





1. Name Of The Medicinal Product



Nitroglycerin Injection U.S.P. 0.05% w/v, 10ml


2. Qualitative And Quantitative Composition



Each 10ml contains 5mg of Nitroglycerin U.S.P.



3. Pharmaceutical Form



Clear, colourless or pale yellow sterile solution intended for parenteral administration to human beings after dilution in either Sodium Chloride Injection B.P. or Glucose Injection B.P.



4. Clinical Particulars



4.1 Therapeutic Indications



a) Control of blood pressure in perioperative hypertension, i.e. hypertension associated with surgical procedures, especially cardiovascular procedures and in the immediate post-surgical period.



b) Unresponsive congestive cardiac failure secondary to acute myocardial infarction.



c) Treatment of angina pectoris in patients who have not responded to recommended doses of organic nitrates and/or beta-adrenoceptor blocking agents.



d) Production of elective hypotension and maintenance of controlled hypotension during surgical procedures.



4.2 Posology And Method Of Administration



Route of administration: Intravenous infusion after dilution.



Nitroglycerin Injection is a concentrated potent drug which must be diluted in either Sodium Chloride Injection B.P. or Glucose Injection B.P. prior to its infusion.



Nitroglycerin Injection should not be mixed with other drugs. It is recommended that the drug is diluted to give a final concentration of 400 micrograms/ml or less, according to the dosage requirements of the patient. Most patients respond to doses between 10 - 200 micrograms/minute, although doses up to 400 micrograms/minute may be required during some surgical procedures.



Dosage: The usual recommended dose range is 10 - 200 micrograms/minute. Doses in excess of these have been used and up to 400 micrograms/minute may be required during some surgical procedures. Careful clinical assessment and frequent monitoring of blood pressure and heart rate are essential to maintain the appropriate rate of infusion. Where available, monitoring of pulmonary capillary wedge pressure and cardiac output can be used to titrate dosage to response.



Surgery: For the control of hypertensive episodes, the recommended starting dose is 25 micrograms/minute increasing in steps of 25 micrograms/minute at 5 minute intervals until the desired reduction in blood pressure is achieved. Although most patients respond to doses between 10 to 200 micrograms/minute, doses up to 400 micrograms/minute have been required during some surgical procedures. In the treatment of perioperative myocardial ischaemia, the recommended starting dose is 15 to 20 micrograms/minute increasing in steps of 10 to 15 micrograms/minute until the desired effect is achieved.



Unresponsive congestive cardiac failure secondary to acute myocardial infarction: The recommended starting dose is 20 to 25 micrograms/minute which can be decreased to 10 micrograms/minute or increased in steps of 20 to 25 micrograms/minute at 15 to 30 minute intervals until the desired effect is achieved.



Unstable angina : The recommended starting dose is 10 micrograms/minute increasing in steps of 5 to 10 micrograms/minute at approximately 30 minute intervals.



Children: The safety and effectiveness of nitroglycerin in children have not been established.



Use in the elderly : Special care in dose titration and monitoring is required in elderly patients, as there is an increased risk of a fall in perfusion pressure owing to a higher prevalence of coronary or cerebral artery disease in the elderly.



4.3 Contraindications



Known hypersensitivity to organic nitrates. Marked anaemia, raised intracranial pressure (e.g. due to head trauma or cerebral haemorrhage), uncorrected hypovolaemia or severe hypotension. Constrictive pericarditis and pericardiac tamponade.



The hypotensive effects of nitrates are potentiated by sildenafil, and their co-administration is contra-indicated.



4.4 Special Warnings And Precautions For Use



Nitroglycerin Injection should be used with caution in patients suffering from severe hepatic or renal disease, hypothyroidism, malnutrition, hypothermia and in those predisposed to closed angle glaucoma.



In order to achieve and maintain the correct dosage, continuous monitoring of physiological parameters must be performed, including blood pressure and heart rate in all patients and other measurements such as capillary wedge pressure as appropriate. The systemic blood pressure and coronary perfusion pressure must be maintained adequately at all times.



Nitroglycerin Injection should be administered by means of a micro-drip set infusion pump or similar device which permits maintenance of a constant infusion rate. The giving set should be composed of glass or rigid polyethylene. Infusion systems composed of PVC may absorb up to 50% of the nitroglycerin from solution, resulting in reduced potency of the infusion (see incompatibilities).



Excessive hypotension, especially for prolonged periods of time, must be avoided because of the possible deleterious effects of poor perfusion on body organs and the consequent risk of ischaemic damage.



Paradoxical bradycardia and increased angina pectoris may accompany nitroglycerin induced hypotension.



Patients with normal or low left ventricular filling pressure or pulmonary capillary wedge pressure are especially sensitive to the hypotensive effects of intravenous nitroglycerin and may respond fully to doses as small as 5 micrograms/minute. Where pulmonary capillary wedge pressure is being monitored, it will be noted that a fall in wedge pressure precedes the onset of arterial hypotension. Therefore, pulmonary capillary wedge pressure is a useful guide to titration of the drug in these circumstances.



Nitroglycerin Injection contains both alcohol and propylene glycol.



Safety for intracoronary injection has not been shown.



Propylene glycol can lead to lacticacidosis and it is recommended that the duration of therapy with this product be restricted to no more than three successive days.



There are no long-term studies to evaluate the carcinogenic potential of nitroglycerin



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Nitroglycerin may potentiate the hypotensive effect of other anti-hypertensive agents. The hypotensive effects of nitrates are potentiated by sildenafil (see Contra-indications).



4.6 Pregnancy And Lactation



There is inadequate evidence of the safety of nitroglycerin in pregnancy and lactation.



Nitroglycerin Injection should not be used during pregnancy or lactation unless considered essential by the physician.



4.7 Effects On Ability To Drive And Use Machines



The indications for Nitroglycerin Injection limit its use to situations in which there would not be an opportunity to drive or to operate machinery.



4.8 Undesirable Effects



Adverse reactions to nitroglycerin may include hypotension, tachycardia, headache, nausea, vomiting, restlessness, dizziness, muscle twitching, palpitation, paradoxical bradycardia, retrosternal discomfort and abdominal pain.



4.9 Overdose



Accidental overdosage may result in severe hypotension and reflex tachycardia which can be managed by elevating the lower limbs and decreasing or temporarily withdrawing the infusion until the condition is stabilised. In extreme states of hypotension, intravenous administration of an alpha adrenergic agonist such as methoxamine hydrochloride or phenylephrine hydrochloride should be considered.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Nitroglycerin is an organic nitrate. Relaxation of vascular smooth muscle is the principal pharmacological action of nitroglycerin. Nitroglycerin causes dilatation of both venous and arterial smooth muscle in a dose-related manner. Venodilatation predominates at lower infusion rates and, as the infusion rate increases, nitroglycerin dilates both arterial and venous systems. Pulmonary vascular resistance, systemic vascular resistance and arterial pressure are all reduced by administration of intravenous nitroglycerin.



Dilatation of the post-capillary vessels promotes peripheral pooling of blood and decreases venous return, reducing left ventricular end-diastolic pressure (pre-load). Relaxation of arterioles reduces systemic vascular resistance and arterial pressure (after-load).



Myocardial oxygen consumption (as measured by the rate-pressure product and tension-time index) is decreased by both the venous and arterial effects of nitroglycerin, and a more favourable supply-demand ratio can be achieved. Although the predominant clinical benefits result from the peripheral vasodilating effects and the resultant decrease in myocardial oxygen demand, some effect on oxygen supply may occur by direct coronary vasodilatation. Redistribution of blood from normal to ischaemic areas of the myocardium has been demonstrated.



5.2 Pharmacokinetic Properties



Pharmacokinetic data for intravenous nitroglycerin are difficult to interpret due to factors such as the variation in sensitivity of assay procedures for calculating plasma concentrations of the drug, intersubject variation in plasma concentrations and adsorption of nitroglycerin by some types of giving sets. There appears to be no close correlation between the infusion rates of intravenous nitroglycerin and the blood concentrations achieved.



Nitroglycerin is extensively distributed and is rapidly metabolised in the liver and erythrocytes by the enzyme glutathione - organic nitrate reductase. The enzyme converts nitroglycerin to dinitrates, mononitrates and inorganic nitrites, which have about one tenth of the vasodilating activity of nitroglycerin and which are excreted in the urine within 24 hours after a single dose. The elimination half-life of nitroglycerin ranges from less than one minute to three minutes. Impaired hepatic function may impair the clearance of the drug.



5.3 Preclinical Safety Data



No further relevant information other than that which is contained in the other sections of the Summary of Product Characteristics.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Propylene Glycol B.P.



Ethanol B.P.



Water for Injections B.P.



6.2 Incompatibilities



Nitroglycerin Injection is compatible with glass infusion bottles. It has been shown to be compatible with certain rigid infusion packs made of polyethylene, such as the polyfusor from Kendall or bottlepak and flatpak from Braun, Dublin. The injection can be administered as an infusion using one of these recommended infusion bottles/packs.



Nitroglycerin Injection is not compatible with infusion bags made from polyvinyl chloride (PVC) and over 40% of the nitroglycerin activity can be lost if contact with PVC is prolonged. Therefore, it is recommended that contact with PVC bags is avoided. Some loss of activity can also occur through the infusion sets but the clinical response should be used to determine the rate of infusion and thus the dosage of the drug required by the patient.



Alternatively, nitroglycerin injection may be infused slowly via a syringe pump using a glass syringe or rigid plastic syringe (Gillette Sabre syringe, Brunswick Disposable, B.D.



Plastipak syringes). A high pressure polyethylene tubing known to be compatible with nitroglycerin is the Lectrocath tubing, Vygon, Gloucester.



6.3 Shelf Life



3 years (36 months).



If only part of an ampoule is used, discard the remaining solution.



6.4 Special Precautions For Storage



Protect from light.



Store in a cool dry place.



6.5 Nature And Contents Of Container



10ml, clear glass ampoules, glass type 1 Ph. Eur., packed in cardboard cartons to contain 5 x 10ml or 10 x 10ml ampoules.



6.6 Special Precautions For Disposal And Other Handling



For administration by i.v. infusion only after dilution with a suitable vehicle such as 5% dextrose in water or 0.9% w/v sodium chloride.



Use as directed by the physician.



Keep out of reach of children.



If only part used, discard the remaining solution.



7. Marketing Authorisation Holder



Antigen International Ltd.,



Roscrea,



Co. Tipperary,



Ireland.



8. Marketing Authorisation Number(S)



PL 2848/0167.



9. Date Of First Authorisation/Renewal Of The Authorisation



29 November 1991.



10. Date Of Revision Of The Text



April 1999




Wednesday, 25 April 2012

Tambocor XL 200mg Capsules





1. Name Of The Medicinal Product



Tambocortm XL 200mg capsules


2. Qualitative And Quantitative Composition



Each capsule contains flecainide acetate 200mg



For excipients see 6.1



3. Pharmaceutical Form



Prolonged release capsule hard.



Size 1 hard gelatin capsule with light grey cap and opaque pink body with 3M 200 printed in black ink.



4. Clinical Particulars



4.1 Therapeutic Indications



Tambocor is a potent sodium channel blocking agent for the treatment of the conditions listed below:



The effect on the JT interval is insignificant at therapeutic levels.



Tambocor XL capsules are indicated for:



a) AV nodal reciprocating tachycardia, arrhythmias associated with Wolff-Parkinson-White Syndrome and similar conditions with accessory pathways.



b) Paroxysmal atrial fibrillation in patients with disabling symptoms when treatment need has been established and in the absence of left ventricular dysfunction (see 4.4, Special warnings and precautions for use).



Arrhythmias of recent onset will respond more readily. Tambocor XL capsules can be used for the maintenance of normal rhythm following conversion by other means.



Tambocor XL capsules are for oral administration.



4.2 Posology And Method Of Administration



The controlled-release form of flecainide acetate is administered as a once-daily dose. Tambocor XL should not be used for control of arrhythmias in acute situations. Treatment should be initiated with either Intravenous or oral Tambocor IR formulations then switched to Tambocor XL.



Adults: Supraventricular arrhythmias: The recommended starting dosage is 50mg twice daily (IR formulation) and most patients will be controlled at this dose. If required the dose may be increased to a maximum of 300mg (IR formulation) daily.



Those patients controlled on 200mg (IR) daily may be switched to one 200mg XL capsule once daily. After 3-5 days it is recommended that the dosage be progressively adjusted to the lowest level which maintains control of the arrhythmia. It may be possible to reduce dosage during long-term treatment.



Children: Tambocor is not recommended in children under 12, as there is insufficient evidence of its use in this age group.



Elderly Patients: The rate of flecainide elimination from plasma may be reduced in elderly people. This should be taken into consideration when making dose adjustments.



Plasma levels: Based on PVC suppression, it appears that plasma levels of 200 – 1000ng/ml may be needed to obtain the maximum therapeutic effect. Plasma levels above 700 – 1000ng/ml are associated with increased likelihood of adverse experiences.



Dosage in impaired renal function: In patients with significant renal impairment (creatinine clearance of 35ml/min/1.73 sq.m. or less) the maximum initial dosage should be 100mg IR daily. When used in such patients, frequent plasma level monitoring is strongly recommended.



It is recommended that intravenous treatment with Tambocor should be administered in hospital.



Treatment with Tambocor XL should be under direct hospital or specialist supervision for patients with:



a) AV nodal reciprocating tachycardia; arrhythmias associated with Wolff-Parkinson-White Syndrome and similar conditions with accessory pathways.



b) Paroxysmal atrial fibrillation in patients with disabling symptoms.



Treatment for patients with other indications should continue to be initiated in hospital.



4.3 Contraindications



Tambocor is contra-indicated in cardiac failure and in patients with a history of myocardial infarction who have either asymptomatic ventricular ectopics or asymptomatic non-sustained ventricular tachycardia.



It is also contra-indicated in patients with long standing atrial fibrillation in whom there has been no attempt to convert to sinus rhythm, and in patients with haemodynamically significant valvular heart disease.



Unless pacing rescue is available, Tambocor should not be given to patients with sinus node dysfunction, atrial conduction defects, second degree or greater atrio-ventricular block, bundle branch block or distal block.



4.4 Special Warnings And Precautions For Use



Electrolyte disturbances should be corrected before using Tambocor.



Since flecainide elimination from the plasma can be markedly slower in patients with significant hepatic impairment, flecainide should not be used in such patients unless the potential benefits clearly outweigh the risks. Plasma level monitoring is strongly recommended in these circumstances.



Tambocor is known to increase endocardial pacing thresholds – i.e. to decrease endocardial pacing sensitivity. This effect is reversible and is more marked on the acute pacing threshold than on the chronic. Tambocor should thus be used with caution in all patients with permanent pacemakers or temporary pacing electrodes, and should not be administered to patients with existing poor thresholds or non-programmable pacemakers unless suitable pacing rescue is available.



Generally a doubling of either pulse width or voltage is sufficient to regain capture, but it may be difficult to obtain ventricular thresholds less than 1 Volt at initial implantation in the presence of Tambocor.



The minor negative inotropic effect of flecainide may assume importance in patients predisposed to cardiac failure. Difficulty has been experienced in defibrillating some patients. Most of the cases reported had pre-existing heart disease with cardiac enlargement, a history of myocardial infarction, arterio-sclerotic heart disease and cardiac failure.



Tambocor should be avoided in patients structural organic heart disease or abnormal left ventricular function.



Tambocor should be used with caution in patients with acute onset of atrial fibrillation following cardiac surgery.



In a large scale, placebo-controlled clinical trial in post-myocardial infarction patients with asymptomatic ventricular arrhythmia, oral flecainide was associated with a 2.2 fold higher incidence of mortality or non-fatal cardiac arrest as compared with its matching placebo. In that same study, an even higher incidence of mortality was observed in flecainide-treated patients with more than one myocardial infarction. Comparable placebo-controlled clinical trials have not been done to determine if flecainide is associated with higher risk of mortality in other patient groups.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Flecainide is a class I anti-arrhythmic and interactions are possible with other anti-arrhythmic drugs where additive effects may occur or where drugs interfere with the metabolism of flecainide. The following known categories of drugs may interact with flecainide:



Cardiac glycosides: Flecainide can cause the plasma digoxin level to rise by about 15%, which is unlikely to be of clinical significance for patients with plasma levels in the therapeutic range. It is recommended that the digoxin plasma level in digitalised patients should be measured not less than six hours after any digoxin dose, before or after administration of flecainide.



Class II anti-arrhythmics: the possibility of additive negative inotropic effects of beta-blockers and other cardiac depressants with flecainide should be recognised.



Class III anti-arrhythmics: when flecainide is given in the presence of amiodarone, the usual flecainide dosage should be reduced by 50% and the patient monitored closely for adverse effects. Plasma level monitoring is strongly recommended in these circumstances.



Class IV anti-arrhythmics: use of flecainide with other sodium channel blockers is not recommended.



Anti-depressants: fluoxetine increases plasma flecainide concentration, increased risk of arrhythmias with tricyclics, manufacturer of reboxetine advises caution.



Anti-epileptics: limited data in patients receiving known enzyme inducers (phenytoin, phenobarbital, carbamazepine) indicate only a 30% increase in the rate of flecainide elimination.



Anti-psychotics: clozapine– increased risk of arrhythmias.



Anti-histamines: increased risk of ventricular arrhythmias with mizolastine and terfenadine (avoid concomitant use).



Anti-malarials: quinine increases plasma concentration of flecainide.



Antivirals: plasma concentration increased by ritonavir, lopinavir and indinavir (increased risk of ventricular arrhythmias, avoid concomitant use).



Diuretics: Class effect due to hypokalaemia giving rise to cardiac toxicity.



Ulcer healing drugs: cimetidine inhibits metabolism of flecainide. In healthy subjects receiving cimetidine (1g daily) for one week, plasma flecainide levels increased by about 30% and the half-life increased by about 10%.



Anti-smoking aids: Co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including flecainide, should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication. If bupropion is added to the treatment regimen of a patient already receiving flecainide, the need to decrease the dose of the original medication should be considered.



Treatment with Tambocor is compatible with use of oral anti-coagulants.



4.6 Pregnancy And Lactation



There is no evidence as to drug safety in human pregnancy. In New Zealand White rabbits high doses of flecainide caused some foetal abnormalities, but these effects were not seen in Dutch Belted rabbits or rats. The relevance of these findings to humans has not been established. Data have shown that flecainide crosses the placenta to the foetus in patients taking flecainide during pregnancy.



Flecainide is excreted in human milk and appears in concentrations which reflect those in maternal blood. The risk of adverse effects to the nursing infant is very small.



4.7 Effects On Ability To Drive And Use Machines



No effect.



4.8 Undesirable Effects



Body as a Whole: Asthenia, fatigue, fever, oedema



Cardiovascular: Pro-arrhythmic effects occur but are most likely in patients with structural heart disease and/or significant left ventricular impairment.



In patients with atrial flutter the use of Tambocor has been associated with 1:1 AV conduction following initial atrial slowing with resultant ventricular acceleration. This has been seen most commonly following the use of the injection for acute conversion. This effect is usually short lived and abates quickly following cessation of therapy.



The following adverse effects have also been reported.



AV block-second-degree and third degree, bradycardia, cardiac failure/congestive cardiac failure, chest pain, hypotension, myocardial infarction, palpitation and sinus pause or arrest and tachycardia (AT or VT).



Skin and Appendages: A range of allergic skin reactions have been reported including rashes and rare but serious reports of urticaria. There have also been isolated cases of photosensitivity.



Immune System: A small number of cases of increases in anti-nuclear antibodies have been reported, with and without systemic inflammatory involvement.



Haematological: Reductions in red blood cells, white blood cells and platelets have been occasionally reported. These changes are usually mild.



Psychiatric: Rarely, hallucinations, depression, confusion, amnesia. Anxiety and insomnia have been reported



Gastrointestinal: Occasionally nausea and vomiting. The following have also been reported: abdominal pain, anorexia, constipation, diarrhoea, dyspepsia and flatulence (bloating).



Liver and Biliary System: A number of cases of elevated liver enzymes and jaundice have been reported in association with Tambocor treatment. So far this has always been reversible on stopping treatment. Hepatic dysfunction has also been reported.



Neurological: Most commonly giddiness, dizziness and lightheadedness, which are usually transient. Rare instances of dyskinesia have been reported, which have improved on withdrawal of flecainide therapy. Rare instances of convulsions, and during long term therapy a few cases of peripheral neuropathy; paraesthesia and ataxia have been reported. There also have been reports of flushing, headache, hypoaesthesia, increased sweating, somnolence, syncope, tinnitus, tremor and vertigo.



Ophthalmological: Visual disturbances, such as double vision and blurring of vision may occur but these are usually transient and disappear upon continuing or reducing the dosage.



Extremely rare cases of corneal deposits have also been reported.



Respiratory: Dyspnoea and rare cases of pneumonitis have been reported



4.9 Overdose



Overdosage with flecainide is a potentially life threatening medical emergency. No specific antidote is known. There is no known way of rapidly removing flecainide from the system, but forced acid diuresis may theoretically be helpful. Neither dialysis nor haemoperfusion is helpful and injections of anticholinergics are not recommended.



Treatment may include therapy with an inotropic agent, intravenous calcium, giving circulatory assistance (e.g. balloon pumping), mechanically assisting respiration, or temporarily inserting a transvenous pacemaker if there are severe conduction disturbances or the patient's left ventricular function is otherwise compromised.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Tambocor is a Class 1 anti-arrhythmic (local anaesthetic) agent.



Tambocor slows conduction through the heart, having its greatest effect on His Bundle conduction. It also acts selectively to increase anterograde and particularly retrograde accessory pathway refractoriness. Its actions may be reflected in the ECG by prolongation of the PR interval and widening of the QRS complex. The effect on the JT interval is insignificant.



5.2 Pharmacokinetic Properties



Tambocor XL capsules contain polymer-coated microgranules, allowing controlled release of the active substance. Each microgranule constitutes a controlled release form of flecainide acetate, allowing prolongation of the absorption time without modifying the elimination parameters.



Absorption of flecainide acetate via the oral route is greater than 80% of the dose administered.



After administration of one XL capsule, plasma flecainide concentrations gradually increase after a lag time of 2 to 3 hours to reach a peak between the 21st and 25th hour and remain at plateau levels until after the 30th hour.



Absorption of flecainide acetate from capsules is not modified by food.



Steady-state is reached after five days of treatment with minimal fluctuations, and 50% flattening of plasma concentration peaks compared to the tablet form.



Flecainide acetate is widely and rapidly distributed in the tissues. The mean volume of distribution is 8.31 l/kg. Protein binding is low (about 40%).



Flecainide acetate is essentially eliminated in the urine: 25% of the dose is eliminated after 24 hours in the unchanged form. Haemodialysis does not appear to be an effective way to eliminate flecainide acetate. Flecainide acetate is also eliminated by metabolism, especially via the cytochrome 2D6 pathway. The apparent plasma elimination half-life is about 12 to 27 hours, it is not modified with the XL capsule form.



No enzyme induction or inhibition phenomena have been observed after prolonged dosing.



5.3 Preclinical Safety Data



Not applicable



6. Pharmaceutical Particulars



6.1 List Of Excipients



Excipients:



Microcrystalline Cellulose



Methacrylic acid-methyl methacrylate (1:2) copolymer



Macrogol 400



Talc



Capsule shell:



Gelatin



Titanium Dioxide (E171)



Iron Oxide Black (E172)



Erythrosine (E127)



Printing ink contains:



Shellac (E904)



Propylene glycol (E1520)



Iron Oxide Black (E172)



6.2 Incompatibilities



None known



6.3 Shelf Life



2 years



6.4 Special Precautions For Storage



Do not store above 25°C. Store in original package.



6.5 Nature And Contents Of Container



UPVC/PVDC/Aluminium blister packs containing 15, 30 or 60 capsules.



6.6 Special Precautions For Disposal And Other Handling



Not applicable.



7. Marketing Authorisation Holder



Meda Pharmaceuticals Ltd



Skyway House



Parsonage Road



Takeley



Bishop's Stortford



CM22 6PU



United Kingdom



8. Marketing Authorisation Number(S)



PL 15142/0076



9. Date Of First Authorisation/Renewal Of The Authorisation



28th April 2005



10. Date Of Revision Of The Text



1st December 2009




Friday, 20 April 2012

Joint




Joint may be available in the countries listed below.


Ingredient matches for Joint



Oxaceprol

Oxaceprol is reported as an ingredient of Joint in the following countries:


  • Argentina

International Drug Name Search

Wednesday, 18 April 2012

Testred


Generic Name: methyltestosterone (METH il tes TOS te role)

Brand Names: Android, Methitest, Testred


What is Testred (methyltestosterone)?

Methyltestosterone is a man-made form of testosterone, a naturally occurring sex hormone that is produced in a man's testicles. Small amounts of testosterone are also produced in a woman's ovaries and adrenal system.


Methyltestosterone is used in men and boys to treat conditions caused by a lack of this hormone, such as delayed puberty or other hormonal imbalances. Methyltestosterone is also used in women to treat breast cancer that has spread to other parts of the body.


Methyltestosterone may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about Testred (methyltestosterone)?


Methyltestosterone can cause birth defects. Do not use if you are pregnant. Use effective birth control, and tell your doctor if you become pregnant during treatment. You should not use this medication if you are allergic to methyltestosterone, or have prostate cancer or male breast cancer.

Before receiving methyltestosterone, tell your doctor if you have benign prostatic hypertrophy, breast cancer, a bleeding or blood clotting disorder, liver or kidney disease, heart disease, coronary artery disease, congestive heart failure, or a history of heart attack.


To be sure this medication is helping your condition, your blood will need to be tested on a regular basis. Do not miss any scheduled visits to your doctor.


Methyltestosterone can affect bone growth in boys who are treated for delayed puberty. Bone development may need to be checked with x-rays every 6 months during treatment.

What should I discuss with my health care provider before taking Testred (methyltestosterone)?


You should not use this medication if you are allergic to methyltestosterone, or have certain conditions. Be sure your doctor knows if you have:

  • prostate cancer;




  • male breast cancer; or




  • if you are pregnant.



Before receiving methyltestosterone, tell your doctor if you are allergic to any drugs, or if you have:



  • benign prostatic hypertrophy (BPH);




  • breast cancer;




  • a bleeding or blood clotting disorder;




  • delayed puberty;




  • liver or kidney disease; or




  • heart disease, coronary artery disease (hardened arteries), congestive heart failure, or a history of heart attack.



If you have any of these conditions, you may need a dose adjustment or special tests to safely take methyltestosterone.


FDA pregnancy category X. This medication can cause birth defects. Do not receive methyltestosterone if you are pregnant. Tell your doctor right away if you become pregnant during treatment. Use an effective form of birth control while you are receiving this medication. It is not known whether methyltestosterone passes into breast milk or if it could harm a nursing baby. Do not receive this medication without telling your doctor if you are breast-feeding a baby. Methyltestosterone can affect bone growth in boys who are treated for delayed puberty. Bone development may need to be checked with x-rays every 6 months during treatment.

How should I take Testred (methyltestosterone)?


Take this medication exactly as prescribed by your doctor. Do not take it in larger amounts or for longer than recommended. Follow the directions on your prescription label.


Your doctor may occasionally change your dose to make sure you get the best results from this medication.


To be sure this medication is helping your condition, your blood will need to be tested on a regular basis. Do not miss any scheduled visits to your doctor.


Methyltestosterone can affect bone growth in boys who are treated for delayed puberty. Bone development may need to be checked with x-rays every 6 months during treatment. Store methyltestosterone at room temperature away from moisture and heat.

What happens if I miss a dose?


Take the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to take the medicine and skip the missed dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention if you think you have used too much of this medicine.

An overdose of methyltestosterone is not expected to cause life-threatening symptoms.


What should I avoid while taking Testred (methyltestosterone)?


Follow your doctor's instructions about any restrictions on food, beverages, or activity while you are using methyltestosterone.


Testred (methyltestosterone) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have any of these serious side effects:

  • feeling short of breath, even with mild exertion;




  • swelling, rapid weight gain;




  • increased or ongoing erection of the penis;




  • bone pain, increased thirst, memory problems, restless feeling, confusion, nausea, loss of appetite, increased urination, weakness, muscle twitching; or




  • nausea, vomiting, stomach pain, loss of appetite, and jaundice (yellowing of the skin or eyes).




Women receiving methyltestosterone may develop male characteristics, which could be irreversible if testosterone treatment is continued. Stop taking this medication and call your doctor at once if you notice any of these signs of excess testosterone:

  • changes in menstrual periods;




  • male-pattern hair growth (such as on the chin or chest);




  • hoarse voice; or



  • enlarged clitoris.

Less serious side effects (in men or women) may include:



  • acne, changes in skin color;




  • breast swelling;




  • male pattern baldness;




  • headache, anxiety, depressed mood;




  • mild nausea;




  • numbness or tingly feeling; or




  • increased or decreased interest in sex.



This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Testred (methyltestosterone)?


The following drugs can interact with methyltestosterone. Tell your doctor if you are using any of these:



  • a blood thinner such as warfarin (Coumadin); or




  • insulin or diabetes medication you take by mouth.



This list is not complete and there may be other drugs that can affect methyltestosterone. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.



More Testred resources


  • Testred Side Effects (in more detail)
  • Testred Use in Pregnancy & Breastfeeding
  • Drug Images
  • Testred Drug Interactions
  • Testred Support Group
  • 0 Reviews for Testred - Add your own review/rating


  • Testred MedFacts Consumer Leaflet (Wolters Kluwer)

  • Testred Prescribing Information (FDA)

  • Android Prescribing Information (FDA)

  • Methyltestosterone Professional Patient Advice (Wolters Kluwer)

  • Methyltestosterone Monograph (AHFS DI)



Compare Testred with other medications


  • Breast Cancer, Palliative
  • Delayed Puberty, Male
  • Hypogonadism, Male
  • Postpartum Breast Pain


Where can I get more information?


  • Your pharmacist can provide more information about methyltestosterone.

See also: Testred side effects (in more detail)


Sunday, 15 April 2012

Emend 3-Day


Generic Name: aprepitant (a PREP i tant)

Brand Names: Emend, Emend 2-Day, Emend 3-Day


What is Emend 3-Day (aprepitant)?

Aprepitant blocks the actions of chemicals in the body that trigger nausea and vomiting.


Aprepitant is used together with other medications to prevent nausea and vomiting that may be caused by surgery or cancer chemotherapy.


Aprepitant is given ahead of time and will not treat nausea or vomiting that you already have.


Aprepitant may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about Emend 3-Day (aprepitant)?


Do not take aprepitant if you are taking any of the following drugs: cisapride (Propulsid) or pimozide (Orap). These drugs may cause life-threatening interactions when taken together with aprepitant. If you have liver disease, you may need an aprepitant dose adjustment or special tests. Aprepitant can make birth control pills less effective, resulting in pregnancy. This effect can last for up to 28 days after your last dose of this medication. Ask your doctor about using a non-hormone method of birth control (such as a condom, diaphragm, spermicide) to prevent pregnancy while taking aprepitant and for at least 1 month after your treatment ends.

There are many other drugs that can interact with aprepitant. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor. Keep a list of all your medicines and show it to any healthcare provider who treats you.


What should I discuss with my health care provider before taking Emend 3-Day (aprepitant)?


You should not use aprepitant if you are allergic to it. These other drugs can cause serious or life-threatening medical problems if you take them together with aprepitant:

  • cisapride (Propulsid); or




  • pimozide (Orap).




If you have liver disease, you may need an aprepitant dose adjustment or special tests. FDA pregnancy category B. Aprepitant is not expected to be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether aprepitant passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I take Emend 3-Day (aprepitant)?


Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.


Aprepitant can be taken with or without food. If you take aprepitant before surgery, follow your doctor's instructions about any restrictions on food or beverages.


The first dose of aprepitant is usually taken 1 hour before treatment with chemotherapy, or 3 hours before a surgery. You may also need additional doses for a couple days after your chemotherapy treatment. Follow your doctor's instructions.


You may also be given other medicines with aprepitant to further help prevent nausea and vomiting.


Aprepitant is not for long-term use.


This medication comes with patient instructions for safe and effective use. Follow these directions carefully. Ask your doctor or pharmacist if you have any questions.


Store at room temperature away from moisture and heat.

What happens if I miss a dose?


Call your doctor for instructions if you forget to take your medicine within the prescribed length of time before your chemotherapy or surgery.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include drowsiness and headache.


What should I avoid while taking Emend 3-Day (aprepitant)?


Follow your doctor's instructions about any restrictions on food, beverages, or activity.


Emend 3-Day (aprepitant) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have a serious side effect such as:

  • feeling like you might pass out;




  • feeling very thirsty or hot, being unable to urinate, heavy sweating, or hot and dry skin; or




  • fever, chills, body aches, flu symptoms, sores in your mouth and throat.



Less serious side effects may include:



  • nausea, vomiting, heartburn, stomach pain;




  • diarrhea or constipation;




  • loss of appetite;




  • hiccups;




  • hair loss;




  • headache;




  • dizziness;




  • tired feeling;




  • mild skin rash;




  • ringing in your ears; or




  • sleep problems (insomnia).



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Emend 3-Day (aprepitant)?


Aprepitant can make birth control pills less effective, resulting in pregnancy. This effect can last for up to 28 days after your last dose of this medication. Ask your doctor about using a non-hormone method of birth control (such as a condom, diaphragm, spermicide) to prevent pregnancy while taking aprepitant and for at least 1 month after your treatment ends.

Tell your doctor about all other medicines you use, especially:



  • tolbutamide (Orinase);




  • a blood thinner such as warfarin (Coumadin);




  • midazolam (Versed) or similar medicines such as Valium, Xanax, or Tranxene;




  • an antidepressant such as nefazodone (Serzone) or paroxetine (Paxil);




  • an antibiotic such as clarithromycin (Biaxin) or rifampin (Rifater, Rifamate);




  • an antifungal medication such as itraconazole (Sporanox) or ketoconazole (Extina, Ketozole, Nizoral, Xolegal);




  • certain cancer medicines such as ifosfamide (Ifex), vinblastine (Velban), or vincristine (Oncovin, Vincasar);




  • HIV medicines such as nelfinavir (Viracept), lopinavir/ritonavir (Kaletra), or ritonavir (Norvir);




  • seizure medication such as carbamazepine (Tegretol, Carbatrol) or phenytoin (Dilantin); or




  • steroid medicine such as dexamethasone (Decadron, Hexadrol) or methylprednisolone (Medapred, Solu-Medrol).



There are many other drugs that may interact with aprepitant. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor. Keep a list of all your medicines and show it to any healthcare provider who treats you.



More Emend 3-Day resources


  • Emend 3-Day Side Effects (in more detail)
  • Emend 3-Day Use in Pregnancy & Breastfeeding
  • Emend 3-Day Drug Interactions
  • Emend 3-Day Support Group
  • 0 Reviews for Emend 3-Day - Add your own review/rating


  • Aprepitant Professional Patient Advice (Wolters Kluwer)

  • aprepitant Advanced Consumer (Micromedex) - Includes Dosage Information

  • Aprepitant MedFacts Consumer Leaflet (Wolters Kluwer)

  • Aprepitant/Fosaprepitant Dimeglumine Monograph (AHFS DI)

  • Emend Prescribing Information (FDA)

  • Emend Consumer Overview



Compare Emend 3-Day with other medications


  • Nausea/Vomiting, Chemotherapy Induced
  • Nausea/Vomiting, Postoperative


Where can I get more information?


  • Your pharmacist can provide more information about aprepitant.

See also: Emend 3-Day side effects (in more detail)